← All organizations
Highest phase reached
Phase 3
Timeline
2000s
- Jun 1, 2003
Clinipace LTD— Founded
2010s
- Sep 25, 2012
Paragon Biomedical— Acquired
- Mar 21, 2013
phenylephrine— NDA Secondary Org
- Apr 1, 2015
Accovion GmbH— Acquired
Drugs by trial phase (22 distinct, 18 trials)
Phase 4 (0 own, 2 via acquisition)
Phase 3 (8 own, 4 via acquisition)
Phase 2 (6 own, 1 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Calcinosis
- Cardiovascular Abnormalities
- Cardiovascular Diseases
- Communicable Diseases
- Esophagitis
- Hepatitis C
- Hepatitis C, Chronic
- Infections
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Respiration Disorders
- Respiratory Tract Diseases
- Rhinitis
- Rhinitis, Allergic
- Vascular Calcification
- Virus Diseases
Marketed drugs (1)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (13)
- NCT04531592CollaboratorPhase 2Jan 31, 2022
- NCT04531579CollaboratorPhase 2Jan 31, 2022
- NCT04652518CollaboratorPhase 2Dec 11, 2020
- NCT04241315CollaboratorPhase 3Mar 26, 2020
- NCT04088721CollaboratorPhase 1/Phase 2Mar 26, 2019
- NCT03113825CollaboratorPhase 2Jul 5, 2017
- NCT03151408CollaboratorPhase 3Jun 1, 2017
- NCT02966028CollaboratorPhase 2Nov 1, 2016
- NCT02914938CollaboratorPhase 1Oct 1, 2016
- NCT04382937CollaboratorPhase 3Jan 12, 2016
- NCT01660633CollaboratorPhase 2Dec 1, 2012
- NCT01660633Study directorPhase 2Dec 1, 2012
- NCT01336530CollaboratorPhase 3Apr 1, 2011
Details
- Founded
- Morrisville, NC, US Jun 1, 2003
- Last known activity
- Jan 31, 2022
Notes
CRO